Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Cosibelimab Under Investigation in Metastatic Cutaneous Squamous Cell Carcinoma

June 1st 2021

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma as part of an ongoing phase 1 study.

Scratching Beneath the Surface in Merkel Cell Carcinoma

May 31st 2021

Due to its rarity, there will likely never be a television advertisement for Merkel cell carcinoma. Yet, several opportunities to help raise awareness and conduct an array of clinical trials are building, due to the disease’s response to checkpoint blockade.

Vidutolimod/Nivolumab Under Evaluation in PD-1–Refractory Advanced Melanoma

May 30th 2021

The safety and efficacy of the combination of vidutolimod and nivolumab is currently under investigation in patients with PD-1–refractory advanced melanoma.

Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma

May 27th 2021

Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.

Immune-Based Combination Regimens Play a Growing Role in MCC

May 27th 2021

Merkel cell carcinoma is a rare, highly aggressive skin tumor associated with the Merkel cell polyomavirus infection, which has been detected in nearly 80% of MCC diagnoses.

Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

May 25th 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma

May 25th 2021

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma

May 20th 2021

Drs Park, Daniels, Sanghvi, and Kolb, discuss two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

May 20th 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma

May 19th 2021

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.

TIL-Based Therapies Possess Potential for Cure in Metastatic Melanoma, But Questions Remain

May 18th 2021

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Dr. Rapisuwon on Clinical Trial Barriers in the United States in Mucosal Melanoma

May 12th 2021

Suthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Dr. Rapisuwon on the Potential Utility of Toripalimab in Melanoma Subtypes

May 4th 2021

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor Types

April 30th 2021

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Dr. Davies on Managing Melanoma During the COVID-19 Pandemic

April 28th 2021

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Dr. Rapisuwon on Frontline Immunotherapy Vs Targeted Therapy in Melanoma Subtypes

April 27th 2021

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma

April 27th 2021

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

First Patients Dosed With PVSRIPO, CT-0508, and TH1902 Boosts Hope for Novel Therapies in Melanoma and Other Solid Tumors

April 22nd 2021

The first patient with PD-1/PD-L1–refractory melanoma has been dosed in the phase 2 LUMINOS-102 trial, which will evaluate the safety and efficacy of PVSRIPO alone or in combination with a PD-1/PD-L1 inhibitor in this patient population.